arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Can-Fite BioPharma Ltd.

CANF

$1.60 ▼ -0.07 (-4.19%) at close

10 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Can-Fite BioPharma Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6M

Dividend Yield —

Revenue Growth -39.9% ↘

Op. Margin None

ROIC -140.6% ↘

FCF / Share $-5.44 ↗

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$405.00K

↓ -39.9% —

Net Income Profit after all expenses

$-9.83M

↓ -24.7% —

FCF / Share Free cash flow per share

$-5.44

↑ +48.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Revenue Growth YoY (%)	-39.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-599%)	-9.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-216%)	-8.3% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-203%)	-5.0% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-163%)	11.8% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+47%)	-62.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-881%)	-46.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-685%)	—	—	—
EPS Growth YoY (%)	45.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-108500.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	66.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-24.7% Weak ↓ Weak Declining Year-over-year change in net income	-3.2% Weak ↓ Weak Declining Year-over-year change in net income	25.0% Good ↑ Good Improving Year-over-year change in net income	19.4% Good ↑ Good Improving Year-over-year change in net income	12.7% Fair ↑ Fair Improving Year-over-year change in net income	-14.4% Weak Weak Year-over-year change in net income	-92.1% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	48.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-159444.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	50.2% Excellent Excellent Year-over-year change in free cash flow	25.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-20.6% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-7.6% Weak ↑ Weak Improving Compound annual revenue growth over 3 years	-0.9% Weak ↑ Weak Improving Compound annual revenue growth over 3 years	-26.4% Weak Weak Compound annual revenue growth over 3 years	-39.3% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—
Revenue CAGR 5Y (%)	-11.9% Weak ↑ Weak Improving Compound annual revenue growth over 5 years	-19.8% Weak Weak Compound annual revenue growth over 5 years	-27.9% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	-141.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1045%)	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	-172.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1533%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	-109.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.11x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Return on Invested Capital (%)	-140.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-118.2% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-103.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-178.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-70.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-183.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-388.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-141.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-104.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-89.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-82.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-108.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-63.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-148.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-146.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-175.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1272%)	-145.0% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1066%)	-122.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-915%)	-227.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1617%)	-87.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-685%)	-237.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1685%)	—	-217.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1553%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Interest Coverage (x)	—	—	—	-131.12x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-713.44x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-614.74x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-414.03x Weak Weak Operating income divided by interest expense Optimal: > 5x	-300.78x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-5.53M	$-4.83M	$-4.28M	$-2.98M	$-4.39M	$-8.27M	$-2.70M	$-3.62M	$-3.50M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Revenue per Share (USD)	$0.25	$0.93	$0.00	$0.00	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-5.97	$-10.86	$-0.01	$-0.01	$-0.03	—	—	—	—	—
Free Cash Flow per Share (USD)	$-5.44	$-10.54	$-0.01	$-0.01	$-0.02	—	—	—	—	—
Book Value per Share (USD)	$2.14	$5.47	$0.00	$0.01	$0.02	$0.01	$0.02	—	—	—
Tangible Book Value per Share (USD)	$2.14	$5.47	$0.00	$0.01	$0.02	$0.01	$0.02	—	—	—
Basic Weighted Avg Shares (shares)	1.65M	725,309	1.28B	815.75M	553.08M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Working Capital (USD)	$6.71M	$6.93M	$7.89M	$6.66M	$17.34M	$8.13M	$3.87M	—	—	—
Total Equity (USD)	$5.59M	$5.44M	$6.24M	$4.47M	$14.38M	$6.07M	$2.44M	$3.02M	$2.98M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Sales/Revenue/Turnover (USD)	$405.00K	$674.00K	$743.00K	$810.00K	$853.00K	$763.00K	$2.03M	$3.82M	—	—
Depreciation Expense (USD)	$24.00K	$7.00K	$15.00K	$14.00K	$14.00K	$12.00K	$14.00K	$14.00K	—	—
Net Income, GAAP (USD)	$-9.83M	$-7.88M	$-7.63M	$-10.17M	$-12.62M	$-14.44M	$-12.62M	$-6.57M	—	$-8.39M
Operating Cash Flow (USD)	$-8.95M	$-7.64M	$-8.44M	$-10.80M	$-9.86M	$-12.06M	$-11.08M	$-4.16M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 9 quarters

Can-Fite BioPharma Ltd.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CANF with peers